Mark Pykett, PhD, Chief Scientific Officer at PTC Therapeutics, discusses his company’s product for Duchenne muscular dystrophy, Translarna.

 

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.